Palisade Bio
PALI
5 hedge funds and large institutions have $1.83M invested in Palisade Bio in 2017 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, reducing their positions, and 2 closing their positions.
5,160% more call options, than puts
Call options by funds: $263K | Put options by funds: $5K
30% more capital invested
Capital invested by funds: $1.41M → $1.83M (+$422K)
0% less ownership
Funds ownership: 0% → 0% (-0%)
17% less funds holding
Funds holding: 6 → 5 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
William Blair & Company
Chicago,
Illinois
|
+$130K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$80K |
| 2 |
ARTA
A.R.T. Advisors
New York
|
-$78K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$40K |
PALI Hedge Fund Activity: Q4 2017 in Review
5 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Palisade Bio (PALI) for Q4 2017, worth a combined $1.83M — up 30% from $1.41M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of PALI and 1 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest buyer was William Blair & Company, opening a new position worth an estimated $130K. The largest seller was Virtu Financial, exiting entirely with an estimated $80K sold.
- 5 institutional investors held Palisade Bio (PALI) as of Q4 2017, down from 6 in Q3 2017.
- Funds reported $1.83M of Palisade Bio stock for Q4 2017, up 30% quarter-over-quarter.
- 1 fund opened new Palisade Bio positions in Q4 2017 and 2 closed out, a net change of -1 holder.
- The largest Palisade Bio buyer in Q4 2017 was William Blair & Company, an estimated $130K added.
- The largest Palisade Bio seller in Q4 2017 was Virtu Financial, an estimated $80K sold.
Based on aggregated 13F filings for Q4 2017.